Allworth Financial LP Has $124,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Allworth Financial LP boosted its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 50.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,582 shares of the company’s stock after buying an additional 3,222 shares during the quarter. Allworth Financial LP’s holdings in Takeda Pharmaceutical were worth $124,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of TAK. Versant Capital Management Inc bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth about $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical during the third quarter worth about $40,000. BNP Paribas Financial Markets grew its holdings in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the last quarter. Smithfield Trust Co lifted its stake in shares of Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Takeda Pharmaceutical in the third quarter worth approximately $52,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $14.08 on Monday. The stock’s 50 day moving average is $13.29 and its 200 day moving average is $13.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm has a market cap of $44.78 billion, a P/E ratio of 35.19, a P/E/G ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.